Literature DB >> 24050237

Animal models in therapeutic drug discovery for oculopharyngeal muscular dystrophy.

Aymeric Chartier, Martine Simonelig.   

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a late onset disease which affects specific muscles. No pharmacological treatments are currently available for OPMD. In recent years, genetically tractable models of OPMDDrosophila and Caenorhabditis elegans – have been generated. Although these models have not yet been used for large-scale primary drug screening, they have been very useful in candidate approaches for the identification of potential therapeutic compounds for OPMD. In this brief review, we summarize the data that validated active molecules for OPMD in animal models including Drosophila, C. elegans and mouse.

Entities:  

Mesh:

Year:  2013        PMID: 24050237     DOI: 10.1016/j.ddtec.2012.07.002

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  3 in total

Review 1.  Recent advances using zebrafish animal models for muscle disease drug discovery.

Authors:  Lisa Maves
Journal:  Expert Opin Drug Discov       Date:  2014-06-14       Impact factor: 6.098

2.  Activation of the ubiquitin-proteasome system contributes to oculopharyngeal muscular dystrophy through muscle atrophy.

Authors:  Cécile Ribot; Cédric Soler; Aymeric Chartier; Sandy Al Hayek; Rima Naït-Saïdi; Nicolas Barbezier; Olivier Coux; Martine Simonelig
Journal:  PLoS Genet       Date:  2022-01-13       Impact factor: 5.917

3.  Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy.

Authors:  Rosemarie H M J M Kroon; Johanna G Kalf; Bert J M de Swart; Barbara M van der Sluijs; Jeffrey C Glennon; Vered Raz; Baziel G van Engelen; Corinne G C Horlings
Journal:  Neurology       Date:  2021-08-11       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.